Re: RVNC-Fosun deal Selling the rights to market RT002 in China for up to $260 million seems low to me. RVNC’s economic interest in the Fosun deal is not $260M, but rather $260M plus royalties. Isn’t China supposed to be the fastest growing market for Botox? China is indeed a fast-growth market for botulinum toxin products generally, but there are several knockoff brands competing for share.